ARCHIVES

Q&A With The Cancer Letter: MD Anderson Provost Had No Say

This article is from The Cancer Letter archive.

Vol. 38 No. 21 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

NCI To Spend About $150 Mil. On Cancers That Affect Only Women

April 26, 1991

Avastin May Trigger Two FDA Decisions: One On Approval, Another On Withdrawal

September 3, 2010

NIH Consensus Conference Concludes That MRI In “Unusually Rewarding,” Calls For More Studies

November 6, 1987

Groups Push for CMS Coverage for LDCT Lung Screening

October 3, 2014

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008